Table 2.
Comparisons of survival outcomes between pCCA patients with high and low NLRs and PLRs.
| Survival outcomes | Total (n = 333) | NLR | PLR | ||||
|---|---|---|---|---|---|---|---|
| < 1.68 (n = 155) | ≥ 1.68 (n = 178) | P value | < 113.1 (n = 231) | ≥ 113.1 (n = 102) | P value | ||
| Period of follow-up, months* | 21.0 (12.0, 36.0) | 27.0 (16.0, 49.0) | 16.5 (8.8, 30.0) | <0.001 | 26.0 (15.0, 45.0) | 12.0 (6.0, 22.3) | <0.001 |
| Death during the follow-up | 234 (70.3%) | 97 (62.6%) | 137 (77.0%) | 0.004 | 146 (63.2%) | 88 (86.3%) | 0.001 |
| Recurrence during the follow-up | 267 (80.1%) | 118 (76.1%) | 149 (83.7%) | 0.084 | 178 (77.1%) | 89 (87.3%) | 0.031 |
| OS, months* | 33.9 (30.8-37.2) | 42.2 (37.4-46.9) | 26.7 (22.6-30.8) | <0.001 | 40.7 (36.8-44.6) | 17.8 (14.1-21.5) | <0.001 |
| 1-yr OS rate, % | 76.1 | 88.3 | 65.4 | 87.4 | 50.3 | ||
| 3-yr OS rate, % | 33.7 | 47.1 | 21.4 | 44.3 | 8.7 | ||
| 5-yr OS rate, % | 22.0 | 30.1 | 14.9 | 29.4 | 3.3 | ||
| RFS, months | 28.2 (25.5-30.9) | 35.5 (31.4-39.6) | 21.6 (18.4-24.7) | <0.001 | 33.9 (30.6-37.0) | 15.0 (11.4-18.6) | <0.001 |
| 1-yr RFS rate, % | 64.0 | 76.7 | 52.9 | 75.2 | 38.3 | ||
| 3-yr RFS rate, % | 33.9 | 47.4 | 21.5 | 43.8 | 10.1 | ||
| 5-yr RFS rate, % | 10.5 | 16.1 | 5.2 | 13.3 | 5.0 | ||
*Values are the mean ± standard deviation or median and quartile.
OS, overall survival; RFS, recurrence-free survival; INR, international normalized ratio; NLR, neutrophil-to-lymphocyte ratio; pCCA, perihilar cholangiocarcinoma; PLR, platelet-to-lymphocyte ratio.